OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting CD39 in cancer
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth
Nature reviews. Immunology (2020) Vol. 20, Iss. 12, pp. 739-755
Closed Access | Times Cited: 250

Showing 1-25 of 250 citing articles:

Immunogenic cell stress and death
Guido Kroemer, Claudia Galassi, Laurence Zitvogel, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 487-500
Open Access | Times Cited: 834

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Kai Li, Houhui Shi, Benxia Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 511

Glioma targeted therapy: insight into future of molecular approaches
Keyang Yang, Zhijing Wu, Hao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 483

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 290

Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Matthew D. Vesely, Tianxiang Zhang, Lieping Chen
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 45-74
Closed Access | Times Cited: 260

Cervical Cancer Immunotherapy: Facts and Hopes
Louise Ferrall, Ken Y. Lin, Richard B.S. Roden, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 18, pp. 4953-4973
Open Access | Times Cited: 257

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 239

Extracellular ATP: A Feasible Target for Cancer Therapy
Valentina Vultaggio-Poma, Alba Clara Sarti, Francesco Di Virgilio
Cells (2020) Vol. 9, Iss. 11, pp. 2496-2496
Open Access | Times Cited: 187

ATP and cancer immunosurveillance
Oliver Kepp, Lucillia Bezu, Takahiro Yamazaki, et al.
The EMBO Journal (2021) Vol. 40, Iss. 13
Open Access | Times Cited: 157

CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 142

CD39 Regulation and Functions in T Cells
Eleonora Timperi, Vincenzo Barnaba
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8068-8068
Open Access | Times Cited: 114

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Huailiang Wu, Yue Gong, Peng Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 106

Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
Jia‐Cheng Lu, Pengfei Zhang, Xiaoyong Huang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 105

Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy
Chi Zhang, Jingsheng Huang, Ziling Zeng, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 102

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Yi Wang, Kai Conrad Cecil Johnson, Margaret E. Gatti‐Mays, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 93

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain
Gennady G. Yegutkin, Detlev Boison
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 799-824
Open Access | Times Cited: 88

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Zhifei Gao, Yifeng Bai, Anqi Lin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 71

Dual‐Cascade Activatable Nanopotentiators Reshaping Adenosine Metabolism for Sono‐Chemodynamic‐Immunotherapy of Deep Tumors
Meixiao Zhan, Fengshuo Wang, Yao Liu, et al.
Advanced Science (2023) Vol. 10, Iss. 10
Open Access | Times Cited: 65

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
Heng-Jia Liu, Heng Du, Damir Khabibullin, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 45

Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations
Si Chen, Bowei Liang, Jianyong Xu
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17

Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy
Rikke Sick Andersen, Atul Anand, Dylan Harwood, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4255-4255
Open Access | Times Cited: 81

Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Céline M. Laumont, Maartje C.A. Wouters, Julian Smazynski, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 14, pp. 4089-4100
Open Access | Times Cited: 80

Local immune recognition of trophoblast in early human pregnancy: controversies and questions
Ashley Moffett, Norman Shreeve
Nature reviews. Immunology (2022) Vol. 23, Iss. 4, pp. 222-235
Open Access | Times Cited: 66

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity
Zhengguo Wu, Shang Li, Xiao Zhu
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 62

Page 1 - Next Page

Scroll to top